Scarica l'app Stockscreener
2.47
0.40%
-0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.48
Aprire:
$2.47
Volume 24 ore:
4.69M
Relative Volume:
0.72
Capitalizzazione di mercato:
$2.55B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-2.5464
EPS:
-0.97
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
+0.41%
1M Prestazione:
-15.12%
6M Prestazione:
-28.20%
1 anno Prestazione:
-52.86%
Intervallo 1D:
$2.39
$2.50
Intervallo di 1 settimana:
$2.39
$3.035
Portata 52W:
$2.28
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Confronta IBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.47 | 2.55B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Yahoo Finance
Economic Uncertainties Batter Trading in These 10 Firms - Insider Monkey
ImmunityBio sees Q1 sales surge, submits FDA applications By Investing.com - Investing.com South Africa
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - BioSpace
ImmunityBio Completes FDA License Application Submissions - MarketScreener
Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia - marketscreener.com
ImmunityBio sees Q1 sales surge, submits FDA applications - Investing.com
Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - Insider Monkey
Is ImmunityBio Stock Heading Upwards? - timothysykes.com
ImmunityBio settles securities class action lawsuit for $10.5 million - Claim Depot
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Insider Monkey
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - Insider Monkey
ImmunityBio secures $75 million in direct offering - Investing.com Australia
ImmunityBio secures $75 million in direct offering By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow
ImmunityBio Stock: What’s Driving the Market? - timothysykes.com
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
ImmunityBio Launches $75 Million Registered Direct Offering - MarketScreener
ImmunityBio (IBRX) Secures $75 Million in Direct Offering - GuruFocus
ImmunityBio raises $75 million in equity financing - MSN
ImmunityBio Secures $75 Million in Direct Offering - TipRanks
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire
IMMUNITYBIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) - ACCESS Newswire
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - BioSpace
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, - GlobeNewswire
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors - TradingView
ImmunityBio: Taking Care Of Business (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio and Beigene to run Phase 3 of Anktiva plus PD-1 in NSCLC - PPF Group
Why ImmunityBio Inc. (IBRX) Went Up Last Week? - Yahoo Finance
Is ImmunityBio, Inc. Stock a Buy Right Now? - timothysykes.com
ImmunityBio’s Recent Surge: What’s Behind It? - timothysykes.com
ImmunityBio to Host Investor Day - BioSpace
Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? - Insider Monkey
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates - EIN News
ImmunityBio appoints Deloitte as new auditor By Investing.com - Investing.com South Africa
ImmunityBio appoints Deloitte as new auditor - Investing.com Australia
Drugmaker's $10.5M Deal In Investor FDA Approval Suit OK'd - Law360
ImmunityBio $10.5 Million Settlement Over Record Selloff Gets OK - Bloomberg Law News
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
H.C. Wainwright maintains $8 target for ImmunityBio stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $8 target for ImmunityBio stock - Investing.com
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):